Elasmogen has been awarded a total of 2 million pounds to support the next generation of biologics

, a derivative of the University of Aberdeen, has announced a follow-up equity investment of a total of 2 million pounds from Deepbridge Capital, bringing its total investment in Elasmogen to 3.15 million pounds.The biopharmaceutical company said the money will be used to accelerate the development of the company's next generation of biologics for delivery and treatment at specific locations for specific drugs.Elasmogen's proprietary humanized version of the drug, also known as SoloMER biologics, was originally based on a protein found in nature called VNAR.
VNAR
small antibody-like protein and a key component of shark immune systems.SoloMER's small size, highly stable properties and simple structure make it "ideal for more effective treatment for diseases such as rheumatoid arthritis and cancer." Caroline Barelle chief executive, said the company was pleased that Deepbridge continued to support its future growth.She continued: "Our preclinical data sets are becoming more and more compelling. These data are turning our original hypothesis about the unique selling point of SoloMER biologics into a scientific reality. In fact, our results now suggest that, at least in the laboratory, our drugs are ten times more potency than existing therapies. Thecompany now has a drug bank of more than 100 billion SoloMER biologics from which new drug cues can be isolated. It is also developing its own internal channels for new drugs and is beginning to develop more and more successful business partnerships. （cyy123.com）